Antiarrhythmic drugs: a reorientation in light of recent developments in the control of disorders of rhythm (Q39449469)

12 September 2017

1 reference

title

Antiarrhythmic drugs: a reorientation in light of recent developments in the control of disorders of rhythm (English)

1 reference

12 September 2017

B N Singh

1

1 reference

12 September 2017

language of work or name

English

0 references

publication date

1 March 1998

1 reference

American Journal of Cardiology

12 September 2017

published in

1 reference

12 September 2017

volume

81

1 reference

12 September 2017

issue

6A

1 reference

12 September 2017

page(s)

3D-13D

1 reference

Expanding indications for the use of Class III agents in patients at high risk for sudden death

12 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Controlling cardiac arrhythmias: an overview with a historical perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

QUINIDINE SYNCOPE. PAROXYSMAL VENTRICULAR FIBRILLATION OCCURRING DURING TREATMENT OF CHRONIC ATRIAL ARRHYTHMIAS.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Effect of Altering Potassium Concentration on the Action of Lidocaine and Diphenylhydantoin on Rabbit Atrial and Ventricular Muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

A third class of anti-arrhythmic action. Effects on atrial and ventricular intracellular potentials, and other pharmacological actions on cardiac muscle, of MJ 1999 and AH 3474

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

The effect of amiodarone, a new anti-anginal drug, on cardiac muscle

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

A fourth class of anti-dysrhythmic action? Effect of verapamil on ouabain toxicity, on atrial and ventricular intracellular potentials, and on other features of cardiac function

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Antiarrhythmic drug classifications. A critical appraisal of their history, present status, and clinical relevance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Comparative mechanisms of action of antiarrhythmic drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Kinetics of onset of rate-dependent effects of Class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

The Sicilian gambit. A new approach to the classification of antiarrhythmic drugs based on their actions on arrhythmogenic mechanisms. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

The coming of age of the class III antiarrhythmic principle: retrospective and future trends

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Cardiac arrhythmias and antiarrhythmic drugs: recent advances in our understanding of mechanism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

An antiarrhythmic drug experience in 941 patients resuscitated from an initial cardiac arrest between 1970 and 1985

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Efficacy and safety of quinidine therapy for maintenance of sinus rhythm after cardioversion. A meta-analysis of randomized control trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Idiopathic long QT syndrome: progress and questions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

A comparison of electrophysiologically guided antiarrhythmic drug therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Beta blockade during and after myocardial infarction: an overview of the randomized trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Double-blind, placebo-controlled study of the effects of carvedilol in patients with moderate to severe heart failure. The PRECISE Trial. Prospective Randomized Evaluation of Carvedilol on Symptoms and Exercise.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

A randomized trial of beta-blockade in heart failure. The Cardiac Insufficiency Bisoprolol Study (CIBIS). CIBIS Investigators and Committees

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Cellular electropharmacology of amiodarone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. Electrophysiologic Study versus Electrocardiographic Monitoring Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Randomized Study of Implantable Defibrillator as First-Choice Therapy Versus Conventional Strategy in Postinfarct Sudden Death Survivors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Channel specificity in antiarrhythmic drug action. Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Electrophysiologic effects of the levo- and dextrorotatory isomers of sotalol in isolated cardiac muscle and their in vivo pharmacokinetics

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Choice and chance in drug therapy of cardiac arrhythmias: technique versus drug-specific responses in evaluation of efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Effects of sodium channel block with mexiletine to reverse action potential prolongation in in vitro models of the long term QT syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Frequency-dependent electrophysiologic effects of amiodarone in humans

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Barium-induced nondriven action potentials as a model of triggered potentials from early afterdepolarizations: significance of slow channel activity and differing effects of quinidine and amiodarone

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Amiodarone-associated proarrhythmic effects. A review with special reference to torsade de pointes tachycardia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Randomized, double-blind comparison of intravenous amiodarone and bretylium in the treatment of patients with recurrent, hemodynamically destabilizing ventricular tachycardia or fibrillation. The Intravenous Amiodarone Multicenter Investigators Grou

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Dose-ranging study of intravenous amiodarone in patients with life-threatening ventricular tachyarrhythmias. The Intravenous Amiodarone Multicenter Investigators Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Therapy of Sustained Ventricular Arrhythmias With Amiodarone: Prediction of Efficacy With Serial Electrophysiologic Studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Intravenous dofetilide, a class III antiarrhythmic agent, for the termination of sustained atrial fibrillation or flutter. Intravenous Dofetilide Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Efficacy and safety of repeated intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Ibutilide Repeat Dose Study Investigators

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Control of cardiac arrhythmias by selective lengthening of repolarization: theoretic considerations and clinical observations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Ibutilide and the treatment of atrial arrhythmias. A new drug--almost unheralded--is now available to US physicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Frequency-dependent Cardiac Electrophysiologic Effects of Tedisamil: Comparison With Quinidine and Sotalol

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Tedisamil Attenuates Ventricular Fibrillation in a Conscious Canine Model of Sudden Cardiac Death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0002-9149%2898%2900147-7

10.1016/S0002-9149(98)00147-7

7 January 2021

Identifiers

DOI

1 reference

12 September 2017

1 reference